ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
2.630
+0.040 (1.54%)
Dec 20, 2024, 4:00 PM EST - Market closed
ProQR Therapeutics Revenue
ProQR Therapeutics had revenue of 3.98M EUR in the quarter ending September 30, 2024, with 190.58% growth. This brings the company's revenue in the last twelve months to 18.39M, up 306.68% year-over-year. In the year 2023, ProQR Therapeutics had annual revenue of 6.59M with 51.27% growth.
Revenue (ttm)
18.39M EUR
Revenue Growth
+306.68%
P/S Ratio
10.46
Revenue / Employee
117,407 EUR
Employees
157
Market Cap
271.43M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 6.59M | 2.24M | 51.27% |
| Dec 31, 2022 | 4.36M | 1.98M | 83.31% |
| Dec 31, 2021 | 2.38M | 1.35M | 131.10% |
| Dec 31, 2020 | 1.03M | -904.00K | -46.77% |
| Dec 31, 2019 | 1.93M | -3.65M | -65.40% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Accolade | 441.03M |
| OraSure Technologies | 224.26M |
| Zynex | 193.67M |
| Lifecore Biomedical | 128.44M |
| AC Immune | 48.51M |
| C4 Therapeutics | 33.67M |
| Lexicon Pharmaceuticals | 5.23M |
| aTyr Pharma | 235.00K |
PRQR News
- 11 days ago - ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist - GlobeNewsWire
- 2 months ago - ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement - GlobeNewsWire
- 2 months ago - ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement - GlobeNewsWire
- 2 months ago - ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares - GlobeNewsWire
- 2 months ago - ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - GlobeNewsWire
- 3 months ago - ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 8 months ago - ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript) - Seeking Alpha
- 8 months ago - ProQR Announces First Quarter 2024 Operating and Financial Results - GlobeNewsWire